BackG&E Herbal Biotechnology , Ltd. Overview

G&E Herbal Biotechnology , Ltd. Current Assets

Track G&E Herbal Biotechnology , Ltd.'s current assets ($470M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$472.26M
↓ 6.75% YoYΔ $-34.19M vs prior year quarter

Peer trimmed avg / median

Loading

G&E Herbal Biotechnology , Ltd. Current Assets History

Loading

G&E Herbal Biotechnology , Ltd. vs. peers: Current Assets Comparison

Loading

G&E Herbal Biotechnology , Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

G&E Herbal Biotechnology , Ltd. (4911.TWO) FAQ

G&E Herbal Biotechnology , Ltd. posts a current assets of $470M as of June 2026. That compares with $510M in the prior-year period — down 6.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, G&E Herbal Biotechnology , Ltd.'s current assets was $510M. The latest reading is $470M — a 6.8% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of G&E Herbal Biotechnology , Ltd.'s financial statement story. At $470M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 4911.TWO's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; G&E Herbal Biotechnology , Ltd.'s other metric pages and overview cover the third.

Judging G&E Herbal Biotechnology , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $470M here, then scan peer and history charts to see if the gap is persistent.